The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Atogepant (Aquipta®) has been accepted for restricted use for the prophylaxis of migraine in adults who have at least 4 migraine days per month. The restriction limits use to patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.
Semaglutide (Wegovy®) has been accepted for restricted use as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
- ≥30kg/m2 (obesity), or
- ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS). In England, this product is recommended for use within a specialist weight management service.
Fenfluramine (Fintepla®) has been accepted for the treatment of seizures associated with Dravet syndrome as an add-on to other anti-epileptic medicines for patients 2 years of age and older. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS). In England, this product is also subject to a commercial arrangement and as such it is expected prescribing would remain with a specialist.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.